고혈압과 고중성지방혈증을 가진 환자에서 혈중 Fenofibrate의 Creatinine 농도에 대한 효과

초록

Objective:Previous studies have reported that fenofibrate therapy increased blood creatinine levels. We investigated the effect of fenofibrate therapy on creatinine levels in patients with hypertension and hypertriglyceridemia. Methods:This retrospective study included 36 hypertensive patients with hypertriglyceridemia taking fenofibrate for 1-3 years (Fenofibrate group) and 36 control patients with similar age, sex, follow-up duration, creatinine levels, and lipid levels to those of fenofibrate therapy (Control group). Results:Baseline parameters except lipid profiles were similar between the fenofibrate and control groups. Creatinine levels increased in the fenofibrate group (from 0.90±0.18 mg/dL to 1.05±0.22 mg/dL, p<0.001) and did not change in the control group (from 0.91±0.12 mg/dL to 0.92±0.14 mg/dL, p=0.39). The elevation was more pronounced in the fenofibrate group than in the control group (0.15±0.12 vs. 0.02±0.11 mg/dL, p<0.001). Changes in creatinine levels were only associated with fenofibrate therapy (r=0.52, p<0.001) in the stepwise linear regression analysis. Conclusion:Fenofibrate therapy for 1-3 years significantly increased creatinine levels in hypertensive patients with hypertriglyceridemia. This finding suggests that follow-up measurement of creatinine level is necessary with fenofibrate therapy.